Newspaper clippings of Financial Results for Q4 & FY26 ended 31 March 2026
HESTERBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Hester Biosciences reported strong financial results for Q4 and full year FY26 ended 31 March 2026. Consolidated total income for FY26 stood at Rs 3,422.83 million, up 8.7% from Rs 3,150.26 million in FY25. Net profit after tax more than doubled to Rs 574.84 million from Rs 255.25 million, representing a 125% increase. Earnings per share doubled to Rs 67.57 from Rs 33.89. Q4 standalone profit after tax was Rs 263.84 million on total income of Rs 978.92 million. The results were published on 16 May 2026 in Financial Express and submitted to exchanges on 18 May 2026.
The doubling of net profit and EPS indicates exceptional operational performance and cost efficiency. This strong recovery in profitability should be positive for the stock, suggesting improved margins and business momentum entering FY27.